pH-Responsive Hyaluronic Acid Nanoparticles for Enhanced Triple Negative Breast Cancer Therapy

References

• Wang J, Zhao H, Zhi K, et al. Exploration of the natural active small-molecule drug-loading process and highly efficient synergistic antitumor efficacy. ACS Appl Mater Interfaces. 2020;12(6):6827–6839. doi:10.1021/acsami.9b18443
   PubMed Web of Science ®Google Scholar
• Ye M, Han Y, Tang J, et al. A tumor-specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers. Adv Mater. 2017;29(38):1702342. doi:10.1002/adma.201702342
   Web of Science ®Google Scholar
• Wang S, Yu G, Wang Z, et al. Enhanced antitumor efficacy by a cascade of reactive oxygen species generation and drug release. Angew Chem Int Ed Engl. 2019;58(41):14758–14763. doi:10.1002/anie.201908997
   PubMed Web of Science ®Google Scholar
• Hou X, Lin H, Zhou X, et al. Novel dual ROS-sensitive and CD44 receptor targeting nanomicelles based on oligomeric hyaluronic acid for the efficient therapy of atherosclerosis. Carbohydr Polym. 2020;232:115787. doi:10.1016/j.carbpol.2019.115787
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu Y, Zang J, et al. Design strategies and applications of ROS-responsive phenylborate ester-based nanomedicine. ACS Biomater Sci Eng. 2020;6(12):6510–6527. doi:10.1021/acsbiomaterials.0c01190
   PubMed Web of Science ®Google Scholar
• He Y, Lei L, Cao J, et al. A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting. Sci Adv. 2021;7(6). doi:10.1126/sciadv.aba0776.
   Web of Science ®Google Scholar
• Zhang M, Qin X, Zhao Z, et al. A self-amplifying nanodrug to manipulate the Janus-faced nature of ferroptosis for tumor therapy. Nanoscale Horiz. 2022;7(2):198–210. doi:10.1039/D1NH00506E
   PubMed Web of Science ®Google Scholar
• Li Q, Zhou Y, He W, et al. Platelet-armored nanoplatform to harmonize janus-faced IFN-gamma against tumor recurrence and metastasis. J Control Release. 2021;338:33–45. doi:10.1016/j.jconrel.2021.08.020
   PubMed Web of Science ®Google Scholar
• Zhou S, Shang Q, Wang N, et al. Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: four birds with one stone. J Control Release. 2020;328:617–630. doi:10.1016/j.jconrel.2020.09.035
   PubMed Web of Science ®Google Scholar
• Zhang M, Qin X, Xu W, et al. Engineering of a dual-modal phototherapeutic nanoplatform for single NIR laser-triggered tumor therapy. J Colloid Interface Sci. 2021;594:493–501. doi:10.1016/j.jcis.2021.03.050
   PubMed Web of Science ®Google Scholar
• Wang P, Gong Q, Hu J, et al. Reactive Oxygen Species (ROS)-responsive prodrugs, probes, and theranostic prodrugs: applications in the ROS-related diseases. J Med Chem. 2021;64(1):298–325. doi:10.1021/acs.jmedchem.0c01704
   PubMed Web of Science ®Google Scholar
• Xu L, Zhao M, Zhang H, et al. Cinnamaldehyde-based poly(ester-thioacetal) to generate reactive oxygen species for fabricating reactive oxygen species-responsive nanoparticles. Biomacromolecules. 2018;19(12):4658–4667. doi:10.1021/acs.biomac.8b01423
   PubMed Web of Science ®Google Scholar
• Chang N, Zhao Y, Ge N, et al. A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer. Drug Deliv. 2020;27(1):1073–1086. doi:10.1080/10717544.2020.1797238
   PubMed Web of Science ®Google Scholar
• Sun B, Luo C, Yu H, et al. Disulfide bond-driven oxidation- and reduction-responsive prodrug nanoassemblies for cancer therapy. Nano Lett. 2018;18(6):3643–3650. doi:10.1021/acs.nanolett.8b00737
   PubMed Web of Science ®Google Scholar
• Liu G, Lovell JF, Zhang L, et al. Stimulus-responsive nanomedicines for disease diagnosis and treatment. Int J Mol Sci. 2020;21(17):6380.
   PubMed Web of Science ®Google Scholar
• Dai L, Li X, Duan X, et al. A pH/ROS cascade-responsive charge-reversal nanosystem with self-amplified drug release for synergistic oxidation-chemotherapy. Adv Sci. 2019;6(4):1801807. doi:10.1002/advs.201801807
   Web of Science ®Google Scholar
• Chen Y, Yao Y, Zhou X, et al. Cascade-reaction-based nanodrug for combined chemo/starvation/chemodynamic therapy against multidrug-resistant tumors. ACS Appl Mater Interfaces. 2019;11(49):46112–46123. doi:10.1021/acsami.9b15848
   PubMed Web of Science ®Google Scholar
• Liu J, Liu W, Weitzhandler I, et al. Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles. Angew Chem Int Ed Engl. 2015;54(3):1002–1006. doi:10.1002/anie.201409293
   PubMed Web of Science ®Google Scholar
• Lu B, Xiao Z, Wang Z, et al. Redox-sensitive polymer micelles based on CD44 and folic acid receptor for intracellular drug delivery and drug controlled release in cancer therapy. ACS Appl Bio Mater. 2019;2(10):4222–4232. doi:10.1021/acsabm.9b00500
   PubMedGoogle Scholar
• Choi KY, Han HS, Lee ES, et al. Hyaluronic acid-based activatable nanomaterials for stimuli-responsive imaging and therapeutics: beyond CD44-mediated drug delivery. Adv Mater. 2019;31(34):e1803549. doi:10.1002/adma.201803549
   PubMed Web of Science ®Google Scholar
• Xu X, Zeng Z, Huang Z, et al. Near-infrared light-triggered degradable hyaluronic acid hydrogel for on-demand drug release and combined chemo-photodynamic therapy. Carbohydr Polym. 2020;229:115394. doi:10.1016/j.carbpol.2019.115394
   PubMed Web of Science ®Google Scholar
• Lu B, Xiao F, Wang Z, et al. Redox-sensitive hyaluronic acid polymer prodrug nanoparticles for enhancing intracellular drug self-delivery and targeted cancer therapy. ACS Biomater Sci Eng. 2020;6(7):4106–4115. doi:10.1021/acsbiomaterials.0c00762
   PubMed Web of Science ®Google Scholar
• Lv Y, Xu C, Zhao X, et al. Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells. ACS Nano. 2018;12(2):1519–1536. doi:10.1021/acsnano.7b08051
   PubMed Web of Science ®Google Scholar
• Liu J, Huang Y, Kumar A, et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014;32(4):693–710. doi:10.1016/j.biotechadv.2013.11.009
   PubMed Web of Science ®Google Scholar
• Kankala RK, Liu CG, Chen AZ, et al. Overcoming multidrug resistance through the synergistic effects of hierarchical pH-sensitive, ROS-generating nanoreactors. ACS Biomater Sci Eng. 2017;3(10):2431–2442. doi:10.1021/acsbiomaterials.7b00569
   PubMed Web of Science ®Google Scholar
• Cao Z, Wang X, Pang Y, et al. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment. Nat Commun. 2019;10(1):5783. doi:10.1038/s41467-019-13727-9
   PubMed Web of Science ®Google Scholar
• Lan S, Liu Y, Shi K, et al. Acetal-functionalized pillar[5]arene: a pH-responsive and versatile nanomaterial for the delivery of chemotherapeutic agents. ACS Appl Bio Mater. 2020;3(4):2325–2333. doi:10.1021/acsabm.0c00086
   PubMedGoogle Scholar
• Xue X, Jin S, Zhang C, et al. Probe-inspired nano-prodrug with dual-color fluorogenic property reveals spatiotemporal drug release in living cells. ACS Nano. 2015;9(3):2729–2739. doi:10.1021/nn5065452
   PubMed Web of Science ®Google Scholar
• Lui G, Shaw R, Schaub FX, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988. doi:10.1016/j.ebiom.2020.102988
   PubMed Web of Science ®Google Scholar
• Zeng F, Ju RJ, Liu L, et al. Efficacy in treating lung metastasis of invasive breast cancer with functional vincristine plus dasatinib liposomes. Pharmacology. 2018;101(1–2):43–53. doi:10.1159/000480737
   PubMed Web of Science ®Google Scholar
• Yao Q, Choi JH, Dai Z, et al. Improving tumor specificity and anticancer activity of dasatinib by dual-targeted polymeric micelles. ACS Appl Mater Interfaces. 2017;9(42):36642–36654. doi:10.1021/acsami.7b12233
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–250. doi:10.1200/JCO.2014.56.2728
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Patail NK, Hirani R, et al. Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors. Clin Cancer Res. 2021;27(6):1792–1806. doi:10.1158/1078-0432.CCR-20-2483
   PubMed Web of Science ®Google Scholar
• Corrales-Sanchez V, Noblejas-Lopez M, Nieto-Jimenez C, et al. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. J Cell Mol Med. 2020;24(5):3117–3127. doi:10.1111/jcmm.14980
   PubMed Web of Science ®Google Scholar
• Leveque D, Becker G, Bilger K, et al. Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clin Pharmacokinet. 2020;59(7):849–856. doi:10.1007/s40262-020-00872-4
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Zeng X, et al. A combined self-assembled drug delivery for effective anti-breast cancer therapy. Int J Nanomedicine. 2021;16:2373–2388. doi:10.2147/IJN.S299681
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng X, Wang H, et al. Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance. Drug Deliv. 2021;28(1):670–679. doi:10.1080/10717544.2021.1905751
   PubMed Web of Science ®Google Scholar
• Fan Y, Wang Q, Lin G, et al. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. Acta Biomater. 2017;62:257–272. doi:10.1016/j.actbio.2017.08.034
   PubMed Web of Science ®Google Scholar
• Sykes EA, Chen J, Zheng G, et al. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 2014;8(6):5696–5706. doi:10.1021/nn500299p
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang F, Liu Y, et al. Glutathione detonated and pH responsive nano-clusters of Au nanorods with a high dose of DOX for treatment of multidrug resistant cancer. Acta Biomater. 2018;75:334–345. doi:10.1016/j.actbio.2018.06.012
   PubMed Web of Science ®Google Scholar
• Zhong Y, Goltsche K, Cheng L, et al. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials. 2016;84:250–261. doi:10.1016/j.biomaterials.2016.01.049
   PubMed Web of Science ®Google Scholar
• Zhu J, Huo Q, Xu M, et al. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy. Nanoscale. 2018;10(38):18387–18397. doi:10.1039/C8NR03899F
   PubMed Web of Science ®Google Scholar